Abstract
Abstract
Linezolid is important for treating infections caused by Gram-positive bacteria resistant to first-line agents. Severe infections often require empirical therapy before pathogen identification and susceptibility testing. This evaluation aims to compare different empirical linezolid dosing strategies in intensive care unit (ICU) patients to improve pharmacokinetic/pharmacodynamic target attainment while minimising toxicities. Three dosing strategies were compared: (i) standard dosing, (ii) therapeutic drug monitoring (TDM)-guided dosing, and (iii) a theoretical model-informed precision dosing (MIPD) strategy based on Bayesian forecasting with a population pharmacokinetic model. Each scenario was combined with an ICU-specific minimal inhibitory concentration (MIC) distribution comprising more than 19,000 isolates collected over 10 years. Data from 117 critically ill patients with 2184 TDM samples were available. Linezolid resistance was highest in ICU isolates (9.6%) compared with isolates from the intermediate care unit (4.3%), general wards (3.6%), and emergency room (1.6%). Among ICU isolates, resistance increased significantly over the 10-year study period, from 6.3% in 2015 to 11.4% in 2024. Empirical target attainment was 36.6% with standard dosing and 48.5% with TDM-guided dose adaptation, in two different ICU cohorts that showed 35.9% and 59.4% baseline target attainment, respectively. Theoretical MIPD projected target attainment in 71.4-81.6% of patients. After excluding resistant isolates, the corresponding values were 40.5%, 53.7%, and 79.0-90.3%, respectively. Integrating a large contemporary ICU-specific MIC distribution with patient-level pharmacokinetic data, our results suggest MIPD may represent a promising strategy improving target attainment, in contrast to standard regimens and TDM-guided dosing which failed to achieve adequate target exposure in ICU patients.
Direct answer
What can I do from this paper page?
Use this page to scan "Empirical linezolid target attainment in critically ill patients: integrating local susceptibility data and dosing strategies" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow Antibiotics Pharmacokinetics and Efficacy research, save the paper, or map adjacent work.
Research areas
Follow related topics
Citation
BibTeX
@article{Starp2026Empirical,
title = {Empirical linezolid target attainment in critically ill patients: integrating local susceptibility data and dosing strategies},
author = {Johannes Starp and Antonia Leonhardt and Jette Jung and Maximilian Sachsenberg Stoschus and Michael Zöller and Christina Scharf and Johannes Zander and Michael Paal and Sebastian G. Wicha and Uwe Liebchen},
journal = {Naunyn-Schmiedeberg s Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-026-06023-z},
url = {https://doi.org/10.1007/s00210-026-06023-z}
}
FAQ
Using this paper in a discovery workflow
How do I find related work for this paper?
Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.
How can I keep up with new Antibiotics Pharmacokinetics and Efficacy research papers?
Follow Antibiotics Pharmacokinetics and Efficacy research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.
Can I cite this paper from this page?
This page includes a static BibTeX block for Empirical linezolid target attainment in critically ill patients: integrating local susceptibility data and dosing strategies. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.
Follow this research in Scollr
Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.
Get the app